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Abstract
Background: The activator protein-1 (AP-1) transcription factor is believed to be important in tumorigenesis and
altered AP-1 activity was associated with cell transformation. We aimed to assess the potential role of AP-1 family
members as novel biomarkers in breast cancer.
Methods: We studied the expression of AP-1 members at the mRNA level in 72 primary breast tumors and 37
adjacent non-tumor tissues and evaluated its correlation with clinicopathological parameters including estrogen
receptor (ER), progesterone receptor (PR) and HER2/neu status. Expression levels of Ubiquitin C (UBC) were used for
normalization. Protein expression of AP-1 members was assessed using Western blot analysis in a subset of tumors. We
used student’s t-test, one-way ANOVA, logistic regression and Pearson’s correlation coefficient for statistical analyses.
Results: We found significant differences in the expression of AP-1 family members between tumor and adjacent
non-tumor tissues for all AP-1 family members except Fos B. Fra-1, Fra-2, Jun-B and Jun-D mRNA levels were
significantly higher in tumors compared to adjacent non-tumor tissues (p < 0.001), whilst c-Fos and c-Jun mRNA levels
were significantly lower in tumors compared with adjacent non-tumor tissues (p < 0.001). In addition, Jun-B
overexpression had outstanding discrimination ability to differentiate tumor tissues from adjacent non-tumor tissues as
determined by ROC curve analysis. Moreover, Fra-1 was significantly overexpressed in the tumors biochemically
classified as ERα negative (p = 0.012) and PR negative (p = 0.037). Interestingly, Fra-1 expression was significantly higher
in triple-negative tumors compared with luminal carcinomas (p = 0.01).
Conclusions: Expression levels of Fra-1 and Jun-B might be possible biomarkers for prognosis of breast cancer.
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Background
Breast cancer is the second most common cancer and
the most common cancer among women in the world
[1]. In addition, breast cancer is a heterogeneous disease
that includes several distinct subtypes with distinctive
gene expression patterns and different overall survival [2].
The treatment of breast cancer has been greatly
advanced in the past decades due to the discovery of
specific predictive and prognostic biomarkers that enable
the application of more individualized therapies to differ-
ent molecular subgroups with distinct clinical behavior
[3]. Among the established biomarkers for breast cancer,
estrogen receptor (ER) is the most powerful predictive
marker both in determining prognosis and predicting
response to hormone therapies [4]. Recently, human epi-
dermal growth factor receptor 2 (HER2) has also become
a routine marker in breast cancer predicting response to
HER2 targeted therapy [5-7]. However, there is clearly a
need to identify additional biomarkers for breast cancer as
all breast cancers do not express ER and/or HER2 and
additionally, there is no perfect correlation between these
biomarkers and the response to targeted treatment.
It is well established that estrogen signaling and ERs
play a central role in the development of breast cancer
[8,9]. Although many of the known effects of estrogen
are mediated via a direct interaction of estrogen with
ERs, ERα and ERβ, which regulate the expression of
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specific sets of genes through a direct interaction with
cis-regulatory elements, estrogen-response elements (EREs),
of target genes [9,10], it is also well established that ERs
interact with DNA indirectly through interaction with
other DNA-bound transcription factors such as activator
protein-1 (AP-1) complexes [11].
The AP-1 transcription factor is a dimeric complex that
includes members of the JUN and FOS protein families.
Unlike the JUN family members (c-Jun, Jun-B, Jun-D), the
FOS family members (c-Fos, Fra-1, Fra-2 and Fos-B) need
to hetrodimerize with members of the JUN family to form
transcriptionally active complexes. After dimerization, AP-1
complexes bind to response elements on DNA including
TPA response elements (TREs) and cAMP response ele-
ments (CREs) in the promoter and enhancer regions of
target genes [12,13]. In vitro studies have shown that
FOS-JUN heterodimers form more stable complexes and
can display stronger DNA-binding activity compared with
JUN homodimers [12,14].
Several studies investigated the expression of FOS and
JUN family members at the mRNA and protein levels in
breast cancer and suggested a role for these proteins as
potential biomarkers in breast cancer [14-18]. However,
a systemic evaluation of the expression of all AP-1 family
members as potential biomarkers in breast cancer is still
lacking.
In the present study we focused on the expression of
c-Fos, Fra-1, Fra-2, Fos-B, c-Jun, Jun-B and Jun-D in
human breast cancer tumors and adjacent non-tumor
tissues with the aim to assay the potential of these mole-
cules as novel biomarkers. Their correlation with ER status,
progesterone receptor (PR) status, HER2 status, lymph
node involvement, stage and grade was further investigated.
Methods
Tissue collection and tumor specimens
Tissue samples of 72 primary breast cancer specimens
(mean age 48.6 years, median age 46.5 years; range 24-
85 years) and 37 adjacent non-tumor tissues were available.
For 36 cases, paired samples from tumor and adjacent
non-tumor tissues were available. Histologically all tumors
were classified as invasive ductal and lobular carcinomas.
ER, PR and HER2 statuses were available in 70, 62 and 68
cases and were positive in 47, 35 and 14 cases, respectively
(Table 1). Receptor status was assessed using Immunohis-
tochemistry (IHC). Fifty-two of the primary breast tumors
were lymph node positive and 20 were lymph node nega-
tive. Thirty-eight patients were premenopausal and 32
postmenopausal, and for two patients the menopausal
status was not available. Forty-two tumors classified as
luminal (ER positive and/or PR positive, and HER2
negative), 10 as triple-negative (ER negative, PR negative
and HER2 negative) and 14 as HER2-enriched (HER2
positive) (Table 1). The pathological staging was done as
recommended by the American Joint Committee on
Cancer (AJCC) TNM system. Eight tumors were classified
as stage I, 37 as stage II, 25 as stage III and 2 as stage IV.
Moreover, 25 patients classified as grade 1, 40 as grade 2,
6 as grade 3 and one as missing. All samples have been
provided from the National Tumor Bank of the Cancer
Institute of Iran. Informed consent was obtained from
all patients who donated samples to the tumor bank.
The National Research Ethics Committee of I.R of Iran
and the Regional Research Ethics committee of Karolinska
Institute approved the study.
Real-time PCR analysis
RNA was extracted from fresh frozen tissues using RNeasy
plus Universal Mini Kits (QIAGEN) according to the
manufacturer’s instructions. The integrity and concen-
tration of the RNA was assessed using the Agilent
Bioanalyzer. Complementary DNA (cDNA) was synthe-
sized using Superscript III First-Strand Synthesis SuperMix
(Invitrogen), according to the manufacturer’s instructions.
One μg RNA from each sample was used as starting
material for cDNA synthesis.
Real-time PCR was run in triplicate in a 7500 ABI
real-time PCR thermocycler (Applied Biosystems). ERα
(ESR1), c-Fos and c-Jun mRNA expression were deter-
mined by TaqMan assay (Hs00174860_s1), TaqMan assay
(Hs04194186_s1) and TaqMan assay (Hs01103582_s1), re-
spectively. The ubiquitin C TaqMan assay (Hs00824723_m1)
was used for normalization. The final volume per well for
Table 1 Clinicopathological data
ER status
Positive (%) 47 (65.3)
Negative (%) 18 (25.0)
Weak (%) 5 (6.9)
Unknown (%) 2 (2.8)
PR status
Positive (%) 35 (48.6)
Negative (%) 25 (34.7)
Weak (%) 2 (2.8)
Unknown (%) 10 (13.9)
HER2 status
Positive (%) 14 (19.4)
Negative (%) 54 (75.0)
Weak (%) 2 (2.8)
Unknown (%) 2 (2.8)
Subtypes of breast cancer
Luminal carcinomas (%) 42 (63.6)
Triple-Negative tumors (%) 10 (15.2)
HER2-enriched tumors (%) 14 (21.2)
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TaqMan assays was 15 μl. SYBR Green assays were used
to determine the mRNA expression for Fra-1 (forward
primer: GGA GGA AGG AAC TGA and reverse primer:
CAC CAA CAT GAA CTC), Fra-2 (forward primer:
AAG CTG CAG GCG GAG and reverse primer: CAC
CAA CAT GAA CTC), Fos-B (forward primer: GAA CGA
AAT AAA CTA and reverse primer: TTT TCT TCC TCC
AAC), Jun-B (forward primer: CGC CGA CGG CTT TGT
and reverse primer: GGT GTC ACG TGG TTC), Jun-D
(forward Primer: CCA GCG AGG AGC AGG and reverse
primer: GCT GGT TCT GCT TGT). The final volume per
well for SYBR Green assays was 10 μl. The thermal cycling
conditions were 95°C for 20 seconds once, then repetitively
95°C for 3 seconds and 60°C for 30 seconds for all assays.
The expression of 16 candidate endogenous control
genes was analyzed by real-time PCR using the TaqMan
Endogenous Control Assay on 16 randomly selected
samples including 11 tumors and 5 adjacent non-tumor
tissues to identify an optimal gene for normalization. The
results showed that ubiquitin C (UBC) displayed the most
stable expression among the samples and it was chosen
for normalization (data not shown). The mRNA expression
was calculated using the ΔCt method by subtracting the
average Ct-value of triplicates of selected genes from the
average Ct-value of triplicates of the housekeeping gene
(UBC) as an internal control.
Western blot analysis
Frozen tumor tissue was minced and cells were lysed with
RIPA/complete mini lysis buffer. Protein extracts were
prepared as described previously [14]. Forty μg of protein
extract was analyzed by Western blot using c-Fos poly-
clonal antibody (H-125) sc-7202 (1:200), Fra-1 polyclonal
antibody (R-20) sc-605 (1:400), Fra-2 polyclonal antibody
(Q-20) sc-604 (1:800), Fos-B polyclonal antibody (102)
sc-48 (1:200), c-Jun polyclonal antibody (H-79) sc-1694
(1:400), Jun-B monoclonal antibody (C-11) sc-8051 (1:100)
and Jun-D polyclonal antibody (329) sc-74 (1:400). All anti-
bodies were purchased from Santa Cruz biotechnology.
Statistical analysis
Student’s t-test was performed to compare continuous
variables between two different categorical clinicopatho-
logical characteristics including ERα, PR, HER2, lymph
node status, and menopausal status. In addition, one-way
ANOVA was used when comparing a continuous variable
with several categorical explanatory variables such as
subtypes of breast cancer, staging and BSR grading system.
Curve estimation regression and logistic regression models
were also fitted with the mRNA expression of AP-1 family
members as the outcome variable.
ROC (Receiving Operating Characteristic) curve test was
used and the area under the curve (AUC) was calculated to
summarize and present the discrimination between tumor
and adjacent non-tumor tissues, as the area under the
curve defined previously [19]. An arbitrary level of 5% for
statistical significance (two-sided) was considered in all
analyses. Statistical analysis was calculated by means of
SPSS statistical software version 16 and R software.
Results
Differential expression for AP-1 family members in
tumors compared to adjacent tissues
The mRNA expression levels of AP-1 family members in
72 mammary carcinomas and 37 adjacent non-tumor
tissues are shown in Figure 1.
Fra-1, Fra-2, Jun-B and Jun-D exhibited significantly
higher expression in tumors compared with adjacent
tissues (p < 0.001). C-Fos and c-Jun mRNA levels were
significantly lower in tumors compared with adjacent
tissues (p < 0.001). Finally, the expression of Fos-B did
not differ between tumor tissue and adjacent tissue.
Repeating the analysis using a paired design, for the 36
individuals where paired samples were available, produced
similar results for the differences in expression levels be-
tween tumor tissue and adjacent tissue (Additional file 1:
Figure S1).
ROC analysis showed that Jun-B overexpression had
outstanding discrimination ability to differentiate tumor
tissue from adjacent non-tumor tissue (AUC = 0.983)
(Figure 2). In addition, Jun-D, Fra-2 and Fra-1 had accept-
able discrimination abilities (AUC= 0.894, 0.811 and 0.782,
respectively) (Table 2).
Pearson’s correlation analysis was performed pairwise
for all seven AP-1 family members the expressions of
which were analyzed in this cross sectional study (Figure 3).
In this analysis, c-Jun and c-Fos showed strong positive
correlation (r = 0.78). In addition, there were moderate
positive correlations between Jun-B and Jun-D (r = 0.63),
and between Fra-2 and Jun-D (r = 0.65). Furthermore,
Jun-D and Jun-B displayed moderate positive correlation
to ERα mNRA levels in ERα positive tumors (n = 47)
(Additional file 1: Figure S2A and S2B).
Association of mRNA expression levels with protein
expression levels
Western blot analysis on six tumor samples demonstrated
correlation between mRNA and protein levels for Fra-1,
Fra-2, Jun-B and Jun-D (Figure 4). Figure 4A and D show
the Western blot analysis for Fra-1, Fra-2, Jun-B and Jun-D,
respectively. Figure 4B,C,E and F show correlations
between mRNA and protein expression levels for Fra-1,
Fra-2, Jun-B and Jun-D, respectively. The samples for
these analyses were chosen based on that they displayed
differential expression of AP-1 family members to allow
correlation between mRNA expression levels and protein
levels. The protein level of c-Jun did not perfectly correlate
with mRNA expression level (data not shown). For c-Fos
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Figure 1 Expression of AP-1 family members comparing tumor and adjacent tissues. The expression of Fra-1 (B), Fra-2 (C), Jun-B (F) and
Jun-D (G) are significantly higher in tumors compared with adjacent tissues (p < 0.001), whereas the expression of c-Fos (A) and c-Jun (E) are
significantly lower in tumors compared with adjacent tissues (p < 0.001). A non-paired model was applied. Gene expression (y-axis) was quantified
by real-time PCR and normalized to UBC.
Figure 2 ROC analyses comparing tumor and adjacent tissues. Jun-B mRNA overexpression had outstanding discrimination ability (AUC =
0.983), and Jun-D, Fra-2 and Fra-1 had an acceptable discrimination ability.
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and Fos-B, protein expression was undetectable presumably
due to low expression as we could detect positive controls
for these proteins in the assays (data not shown).
Fra-1 is overexpressed in triple-negative breast tumors
We classified the breast cancer tumors into different
subtypes based on IHC staining as defined by O'Brien
et al. [20]. ANOVA analysis revealed a significant differ-
ence among subtypes of breast cancer for Fra-1 expression
(p = 0.039) (Table 3 and Figure 5C). Further analysis
showed that Fra-1 mRNA expression was significantly
higher in triple-negative tumors compared with luminal
carcinomas (p = 0.01). However, the difference between
the transcript levels in TNBC and HER2-enriched breast
cancers was not statistically significant. When comparing
the mRNA expression of AP-1 family members with
known molecular markers of breast cancer, Fra-1 was
significantly higher expressed in tumors classified as
ERα negative tumors compared with ERα positive tumors
(p = 0.012) (Figure 5A). Similarly, the expression level
of Fra-1 was significantly higher in PR negative tumors
compared with PR positive tumors (p = 0.037) (Figure 5B).
Additionally, there was no correlation between the mRNA
expression of other JUN and FOS family members and
hormone receptor status.
Association of AP-1 mRNA levels with clinical
characteristics
We investigated the mRNA expression of AP-1 family
members in relation to clinical characteristics such as
clinical staging, histological grading, lymph node and
menopausal statuses and age. We found significant
associations between the expression of c-Fos and Fos-B
with histological grading, with about 40 percent lower ex-
pression of c-Fos [Odds ratio (OR) = 0.62, 95% confidence
interval (CI): 0.42 - 0.94] and Fos-B (OR = 0.62, 95% CI:
0.41 - 0.93) in grade two compared with grade one
(Table 4). In addition, there were significant associations
between the expressions of c-Fos (p = 0.02), Fra-1 (p = 0.05)
and Jun-B (p < 0.0.1) with stage, where the lowest ex-
pression levels were observed for the combined stages
III and IV compared with the other stages. Moreover,
Table 2 Area Under the Curve (AUC) of ROC analysis
Test result variable(s) AUC
Jun-B mRNA Level 0.983
Jun-D mRNA Level 0.894
Fra-2 mRNA Level 0.811
Fra-1 mRNA Level 0.782
Fos-B mRNA Level 0.522
c-Jun mRNA Level 0.258
c-Fos mRNA Level 0.230
The minimum value of AUC is 0.5; the maximum is 1. Jun-B overexpression
has outstanding discrimination ability, and also Jun-D, Fra-2 and Fra-1 have
acceptable discrimination abilities.
Figure 3 Heat map of the Pearson’s correlation matrix for the mRNA expression of AP-1 members. Pairwise correlation analyses were
performed for all assayed mRNAs. Blue represents positive correlation for a given gene pair, and red represents negative correlation. C-Jun and
c-Fos showed strong positive correlation (r = 0.78). In addition, there were moderate positive correlations between Jun-B and Jun-D (r = 0.63), and
between Fra-2 and Jun-D (r = 0.65).
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when comparing the mRNA expression of AP-1 family
members according to menopausal status, we found a
higher expression of Jun-D in premenopausal patients
compared with postmenopausal patients (OR = 0.55,
95% CI: 0.30 - 0.99) (Table 5). Furthermore, we observed
more than 50% lower expression of Fra-1 and Jun-B in
tumors with lymph node involvement compared to tumors
without lymph node involvement, where the ORs were
0.43 (95% CI: 0.22-0.83) and 0.43 (95% CI: 0.20-0.92),
respectively (Tables 4 and 5). Additionally, since age might
play a role as a potential confounder in the association
of AP-1 mRNA levels with clinical characteristics, we
correlated the mRNA expression levels of selected genes
with age, and we found no correlation between mRNA
expression levels of selected genes and age (data not
shown).
Discussion
In the present study, we conducted a comprehensive
analysis of mRNA expression levels of AP-1 family
Figure 4 Western blot analyses showing consistency between protein and mRNA expression levels in breast tumors. Equal amounts of
protein (40 μg) from 6 tumor tissues were loaded. β-actin was used as loading control. For Fra-1 and Jun-D, two bands with apparent molecular
weights of approximately 40 and 42 KDa, and approximately 38 and 40 KDa were observed, respectively. Figures 4A and 4D show the Western
blot analysis for Fra-1, Fra-2, Jun-B and Jun-D, respectively. The results of protein expression levels were compared with the corresponding mRNA
expression levels showing good correlation between mRNA and protein expression levels for Fra-1 (R2 = 0.95), Fra-2 (R2 = 0.74), Jun-B (R2 = 0.74)
and Jun-D (R2 = 0.77). Figure 4B,C,E and F show correlations between mRNA and protein expression levels for Fra-1, Fra-2, Jun-B and
Jun-D, respectively.
Table 3 Analyses of mRNA expression of AP-1 family members in relation to subtypes of breast cancer
Mean (±SD) P Value
(Among subtypes)Variable Luminal tumors Triple-negative tumors HER2-enriched tumors
c-Fos mRNA Level 0.024 ± 0.038 0.012 ± 0.014 0.011 ± 0.009 0.834
Fra-1 mRNA Level 0.024 ± 0.026 0.051 ± 0.043 0.026 ± 0.019 0.039*
Fra-2 mRNA Level 0.330 ± 0.439 0.381 ± 0.253 0.197 ± 0.155 0.238
Fos-B mRNA Level 0.189 ± 0.283 0.090 ± 0.120 0.082 ± 0.108 0.214
c-Jun mRNA Level 0.076 ± 0.065 0.044 ± 0.027 0.068 ± 0.037 0.460
Jun-B mRNA Level 0.885 ± 0.612 1.327 ± 1.655 0.983 ± 0.695 0.708
Jun-D mRNA Level 0.475 ± 0.407 0.398 ± 0.235 0.490 ± 0.280 0.893
One-way ANOVA was used to calculate the p values among different subtypes. Fra-1 expression showed a significant difference among subtypes.
*Post-hoc analysis using LSD revealed that Fra-1 expression was significantly higher in triple-negative tumors compared with luminal carcinomas (p = 0.01).
In addition, Fra-1 expression was marginally significantly higher in triple-negative tumors compared with HER2-enriched (p = 0.067).
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Figure 5 mRNA expression of Fra-1 in relation to ER status, PR status and breast cancer subtypes. The expression of Fra-1 is higher in
tumors classified as ER negative and PR negative tumors compared with ER and PR positive tumors (p = 0.012 and p = 0.037, respectively)
(A and B). In addition, Fra-1 was significantly higher expressed in triple-negative tumors compared with other groups (p = 0.039) (C). Gene
expression (y-axis) was quantified by real-time PCR and normalized to UBC.
Table 4 ORs and 95% CIs for FOS member mRNA expression in tumors with clinicopathological parameters
Parameter OR (95% CI)
c-Fos Fra-1 Fra-2 Fos-B
Menopausal status
Pre-menopause 1 1 1 1
Post-menopause 0.95 (0.71-1.26) 1.24 (0.72-2.14) 0.78 (0.48-1.26) 0.84 (0.60-1.19)
P value 0.71 0.43 0.32 0.33
Lymph node status
Negative 1 1 1 1
Positive 0.72 (0.50-1.06) 0.43 (0.22-0.83) 0.83 (0.49-1.41) 1.00 (0.70-1.46)
P value 0.09 0.01* 0.49 0.98
Stage
I 1 1 1 1
II 1.18 (0.70-2.01) 0.71 (0.29-1.75) 0.83 (0.38-1.82) 1.02 (0.58-1.78)
III and IV 0.75 (0.44-1.26) 0.37 (0.14-0.99) 0.78 (0.35-1.76) 0.86 (0.48-1.53)
P value 0.02* 0.05* 0.84 0.64
Grade
1 1 1 1 1
2 0.62 (0.42-0.94) 0.99 (0.56-1.76) 1.14 (0.62-1.90) 0.62 (0.41-0.93)
3 0.70 (0.37-1.29) 1.15 (0.42-3.17) 1.23 (0.50-3.04) 0.73 (0.37-1.44)
P value 0.04* 0.95 0.83 0.05*
ORs and CIs from logistic regression model, stratified on some parameters including menopausal and lymph node statuses, grade and stage.
Abbreviations: OR, Odds ratio; CI, Confidence interval.
*Statistically significant (p < 0.05 in two-tailed test).
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members in 72 primary breast tumors and 37 adjacent
tissues. However, this approach has its limitations when
addressing the correlation of biomarkers with tumor
development. Future studies could be designed to also
allow sampling of normal breast tissue. However, also
this approach has limitations because the percentage
of epithelial cells is generally higher in breast cancer
tissue. Analysis of samples after microdissection of the
corresponding cell types from tumor and adjacent tissue as
well as normal breast tissue would constitute an important
development to identify tumor biomarkers.
The median age of the studied population at the time
of diagnosis was 46.5 years. This is lower than the median
age for breast cancer diagnosis worldwide [21]. The lower
median age at diagnosis is consistent with the established
younger age at diagnosis of breast cancer in developing
countries [22,23], which is believed to relate to the youn-
ger population in developing countries [24], which cause
higher number of young patients.
In this study we observed that c-Fos and c-Jun were
significantly lower expressed in tumors compared with
adjacent tissues. Whereas, Fra-1, Fra-2, Jun-B and Jun-D
were significantly higher expressed in tumors compared
with adjacent tissue. Finally, our analysis suggests that
two members of the AP-1 family members, Fra-1 and
Jun-B are associated with clinical parameters and thus
might provide novel markers for breast cancer. Taking
into consideration the efficiency of the different PCR
reactions, we estimate that across all samples, Jun B is
expressed at the highest level followed by Jun-D. C-Jun
and c-Fos and Fra-2 are expressed at about equal levels
while Fos-B and Fra-1 are expressed at a lower level as
determined from this analysis (Data not shown).
Consistent with previous reports, our results revealed
that c-Fos and c-Jun are expressed at a higher level in
adjacent tissues compared with tumors [13,25]. Smith et
al investigated the expression and activity of the AP-1
complex in human mammary epithelial cells (HMECs) at
different stages including normal, immortal, oncogene-
transformed and cancer. They showed that normal cells
and immortal HMECs have higher mRNA and protein
expression levels of c-Fos and c-Jun compared with human
breast cancers [25].
Our results showing high expression of Fra-1 in breast
tumors and its differential expression between ERα positive
and ERα negative tumors are consistent with previous stud-
ies [14,17,26,27]. Fra-1 was significantly higher expressed
in triple-negative tumors compared with other groups
(Figure 5C). However, the difference between the tran-
script levels in TNBC and HER2-enriched breast cancers
was only marginally statistically significant (p = 0.067).
Thus, Fra-1 would not appear to define an auxiliary diag-
nostic marker for TNBC, which is clearly need in light of
the remarkable challenges that this breast cancer subtype
presents to researchers and clinicians. In vitro studies
have shown that Fra-1 expression is associated with cell
motility, proliferation and invasiveness [28]. However,
our findings showed that the expression of Fra-1 was
significantly higher in nodal negative tumors compared
with nodal positive tumors, and furthermore no correlation
was observed between Fra-1 expression and metastasis
status. In a cohort study Schroder et al. investigated Fra-2
mRNA expression in 167 patients and found significant
correlations of high Fra-2 expression with younger age,
nodal involvement, high grading and ER negative tumors
[18]. However, our findings did not show any association
of Fra-2 mRNA expression with ER or nodal status and
grading.
Our results demonstrated that there was a significant
association between increased Jun-B mRNA expression
and reduced tumor size and tumor stage. Moreover, Jun-B
mRNA expression was significantly higher in nodal negative
tumors compared with nodal positive tumors. These
findings imply that increased Jun-B expression could be
related to a less aggressive tumor behavior. These results
are similar with previous studies suggesting that Jun-B
could have a role as a tumor suppressor [15].
Table 5 ORs and 95% CIs for JUN member mRNA
expression with clinicopathological parameters
Parameter OR (95% CI)
c-Jun Jun-B Jun-D
Menopausal status
Pre-menopause 1 1 1
Post-menopause 0.80 (0.49-1.3) 0.77 (0.42-1.41) 0.55 (0.30-0.99)
P value 0.36 0.40 0.04*
Lymph node status
Negative 1 1 1
Positive 0.84 (0.48-1.45) 0.43 (0.20-0.92) 0.95 (0.52-1.71)
P value 0.52 0.03* 0.86
Stage
I 1 1 1
II 1.49 (0.67-3.30) 0.65 (0.22-1.97) 1.40 (0.59-3.33)
III and IV 0.881 (0.40-1.92) 0.25 (0.07-0.82) 0.93(0.39-2.23)
P value 0.14 < 0.01** 0.37
Grade
1 1 1 1
2 0.66 (0.37-1.192) 0.56 (0.28-1.13) 1.11 (0.63-1.95)
3 0.54 (0.21-1.36) 0.65 (0.20-2.13) 0.98 (0.37-2.63)
P value 0.26 0.24 0.92
ORs and CIs from logistic regression model, stratified on parameters including
menopausal and lymph node statuses, grade and stage.
Abbreviations: OR, Odds ratio; CI, Confidence interval.
*Statistically significant (p < 0.05 in two-tailed test).
**Statistically significant (p < 0.01 in two-tailed test).
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Milde-Langosch et al. investigated Fos-B mRNA and
protein expression in human breast tumors and normal
breast tissues and showed that Fos-B was highly expressed
in normal lobules and ducts with carcinomas frequently
displaying loss of expression and weak immunostaining.
They showed that Fos-B might be necessary for normal
proliferation and differentiation of mammary epithelial
cells and also Fos-B is down-regulated in poorly differenti-
ated breast tumors [29]. Our results, displaying a margin-
ally significant association between increased Fos-B mRNA
expression and well-differentiated status are consistent
with this report. In contrast, our findings did not show a
significant difference in Fos-B expression between tumors
and adjacent tissues.
There was no clear correlation between expression of
AP-1 members in tumors versus surrounding tissues and
the expression in higher grade and higher stage tumors.
For example c-Fos was lower expressed in tumors versus
surrounding tissues and the expression was also lower in
higher grade and higher stage tumors while Jun-B expres-
sion was higher in tumors compared to surrounding tissues
while the expression was lower in higher grade and stage
tumors.
In this study we focus on the JUN and FOS family mem-
bers of the AP-1 family of transcription factors. However
additionally, members of the ATF (activating transcription
factor) and MAF (musculoaponeurotic fibrosarcoma)
protein families have been shown to contribute to this
complex and could thus be considered as potential
additional biomarkers in breast cancer.
Conclusions
Overall, our findings reveal, among others, that Fra-1
mRNA levels are higher in ERα negative and PR negative
breast cancer tumors. In addition, Jun-B overexpression
has outstanding discrimination ability (AUC = 0.983) to
differentiate tumor tissues from adjacent tissues. We
therefore suggest that AP-1 family members should be
further evaluated in larger cohorts as possible biomarkers
in breast cancer.
Additional file
Additional file 1: Figure S1. Expression of AP-1 family members
comparing tumor and adjacent tissues. The expression of Fra-1
(B), Fra-2 (C), Jun-B (F) and Jun-D (G) are significantly higher in
tumors compared with adjacent tissues (p < 0.001), whereas the
expression of c-Fos (A) and c-Jun (E) are significantly lower in
tumors compared with adjacent tissues (p < 0.001). A paired model
was applied. Gene expression (y-axis) was quantified by real-time
PCR and normalized to UBC. Figure S2. mRNA levels of ERα
display a positive correlation with mRNA levels of Jun-B and Jun-D.
mRNA levels of ERα displayed a significant positive correlation with
mRNA levels of Jun-B and Jun-D among ERα positive tumors (n = 47).
ERα, Jun-B and Jun-D mRNA levels were quantified by real-time PCR
and normalized to UBC.
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